Physician profile
Vitaliy Zhivotenko
NPI 1336431907
$2,971.09
in general payments reported to CMS, 2019-2025
33 companies · $23.96 in 2025
The $23.96 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $734 · 2020: $449 · 2021: $926 · 2022: $403 · 2023: $378 · 2024: $57.87 · 2025: $23.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $459.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $475.11 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $446.30 | 2019-2023 | Relistor |
| Abbvie INC. | $294.45 | 2021-2024 | Qulipta |
| Mml US, INC. | $237.48 | 2023 | Reactiv8 |
| Relievant Medsystems, INC. | $180.92 | 2019 | |
| Lilly USA, LLC | $165.52 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $159.58 | 2020-2021 | |
| Biodelivery Sciences International, INC. | $90.81 | 2020-2021 | |
| Si-Bone, INC. | $83.71 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $79.31 | 2020-2023 | Xtampza |
| Astrazeneca Pharmaceuticals LP | $69.12 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $68.56 | 2022 | |
| Horizon Therapeutics Plc | $55.60 | 2021-2022 | |
| Pacira Therapeutics, INC. | $50.29 | 2019-2020 | |
| Amgen INC. | $43.81 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spinefrontier, INC. | $39.53 | 2020 | |
| Medtronic USA, INC. | $39.40 | 2019-2020 | |
| Boston Scientific Corporation | $38.92 | 2020-2024 | |
| Biogen, INC. | $35.17 | 2021 | |
| Nevro Corp. | $34.88 | 2022 | |
| Painteq LLC | $31.82 | 2021 | |
| Almatica Pharma LLC | $28.57 | 2021 | |
| Abbott Laboratories | $28.35 | 2023 | Proclaim |
| Vertex Pharmaceuticals Incorporated | $23.96 | 2025 | |
| Alexion Pharmaceuticals, INC. | $23.88 | 2022 | |
| Assertio Therapeutics, INC. | $22.40 | 2019 | |
| Alkermes, INC. | $21.00 | 2019 | |
| Indivior INC. | $20.88 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $20.84 | 2023 | Zilretta |
| Virtus Pharmaceuticals LLC | $18.94 | 2021 | |
| Pfizer INC. | $14.61 | 2023 | |
| Sanofi-Aventis U.S. LLC | $14.28 | 2022 | |
| Baudax Bio INC. | $13.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vitaliy Zhivotenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.